• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    3/15/24 1:31:09 PM ET
    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRV alert in real time by email

    Gainers

    • Better Therapeutics (NASDAQ:BTTX) shares increased by 65.4% to $0.06 during Friday's regular session. The market value of their outstanding shares is at $3.1 million.
    • Carmell (NASDAQ:CTCX) shares rose 38.52% to $3.2. The market value of their outstanding shares is at $73.8 million.
    • P3 Health Partners (NASDAQ:PIII) stock rose 38.23% to $0.98. The market value of their outstanding shares is at $112.5 million.
    • Akebia Therapeutics (NASDAQ:AKBA) shares rose 28.1% to $1.75. The market value of their outstanding shares is at $330.6 million. The company's, Q4 earnings came out yesterday.
    • Acrivon Therapeutics (NASDAQ:ACRV) shares increased by 26.03% to $6.39. The market value of their outstanding shares is at $141.8 million.
    • DIH Holding US (NASDAQ:DHAI) stock rose 21.22% to $1.28. The market value of their outstanding shares is at $52.1 million.

    Losers

    • SELLAS Life Sciences Gr (NASDAQ:SLS) shares decreased by 28.7% to $1.1 during Friday's regular session. The company's market cap stands at $48.0 million.
    • Immuneering (NASDAQ:IMRX) shares fell 28.45% to $2.08. The company's market cap stands at $60.7 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock decreased by 25.64% to $1.24. The market value of their outstanding shares is at $2.1 million.
    • Atreca (NASDAQ:BCEL) stock fell 17.54% to $0.16. The market value of their outstanding shares is at $6.5 million.
    • Jin Medical International (NASDAQ:ZJYL) shares fell 17.3% to $4.4. The market value of their outstanding shares is at $688.8 million.
    • Psyence Biomedical (NASDAQ:PBM) stock declined by 17.3% to $1.31. The market value of their outstanding shares is at $17.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRV
    $AKBA
    $BCEL
    $BTTX

    CompanyDatePrice TargetRatingAnalyst
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    Akebia Therapeutics Inc.
    $AKBA
    6/4/2025$8.00Buy
    H.C. Wainwright
    Acrivon Therapeutics Inc.
    $ACRV
    5/5/2025$6.00Overweight
    Piper Sandler
    Akebia Therapeutics Inc.
    $AKBA
    4/28/2025$7.00Outperform
    Leerink Partners
    Akebia Therapeutics Inc.
    $AKBA
    4/1/2025$6.00Buy
    Jefferies
    Acrivon Therapeutics Inc.
    $ACRV
    1/31/2025Overweight
    KeyBanc Capital Markets
    Immuneering Corporation
    $IMRX
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    SEC Filings

    View All

    Acrivon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    2/27/26 9:00:12 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Akebia Therapeutics Inc.

    10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:35:08 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:04:39 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blume-Jensen Peter covered exercise/tax liability with 14,265 shares (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    2/24/26 4:12:46 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 116 shares, decreasing direct ownership by 3% to 4,006 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    2/18/26 4:14:35 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Miller Mary covered exercise/tax liability with 217 shares, decreasing direct ownership by 0.64% to 33,679 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    2/18/26 4:12:42 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET at the TD Cowen 46th Annual Health Care Conference in Boston. The live and archived webcast of this event can be acces

    2/24/26 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

    Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data at the congress WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology compa

    2/23/26 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street resumed coverage on P3 Health Partners with a new price target

    Lake Street resumed coverage of P3 Health Partners with a rating of Buy and set a new price target of $20.00

    8/28/25 8:10:21 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

    6/4/25 7:33:29 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Financials

    Live finance-specific insights

    View All

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A

    2/19/26 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

    Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d

    1/8/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AKBA
    $BCEL
    $BTTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care